Business ❯ Finance ❯ Mergers and Acquisitions

Pharmaceuticals

Oncology Eli Lilly Obesity Drugs Drug Development Alkermes and Avadel Pharmaceuticals Sun Pharma Sun Pharmaceutical Industries Biotech Companies Rare Diseases Torrent Pharmaceuticals Neurological Disorders Sanofi Metsera Lundbeck Gilead Sciences Sun Pharmaceutical Industries Limited Biontech-Curevac Acquisition Royalty Agreements Pfizer Biogen Evoke Pharma, Inc. Bidding Wars Cancer Drug Development Regulatory Approval Merck Biotechnology Walgreens Business Sale Novo Holdings Acquisition Organon & Co. GSK Acquisition of Rapt Therapeutics Biopharmaceuticals Nutrition Generic Drugs Immunology Novo Nordisk Anti-obesity Drugs Market Impact Biosimilars Biogen Acquisition of Apellis Acquisition of Amicus Therapeutics COPD Treatments Pfizer Inc. Ophthalmology Legal Disputes JB Chemicals Industry Trends GSK Cidara Therapeutics Biogen and Apellis Acquisition Biotech Arcellx Antitrust Issues Supernus Pharmaceuticals Company Acquisitions Gene Therapy Weight Loss Drugs Cardiovascular Drugs 23andMe

23 ARTICLES

last wk.

GSK to Buy Nuvalent for $10.6 Billion to Bolster Lung‑Cancer Pipeline

The all‑cash purchase adds two late‑stage targeted lung‑cancer drugs under FDA review and signals CEO Luke Miels’s push to rebuild GSK’s oncology business.

6 ARTICLES

last mo.

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

14 ARTICLES

3mo ago

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

7 ARTICLES

4mo ago

Merck Ends Revolution Medicines Takeover Talks After Valuation Standoff

11 ARTICLES

5mo ago

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

4 ARTICLES

7mo ago

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

11 ARTICLES

7mo ago

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

17 ARTICLES

7mo ago

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

18 ARTICLES

7mo ago

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

20 ARTICLES

7mo ago

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

6 ARTICLES

7mo ago

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

4 ARTICLES

8mo ago

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

27 ARTICLES

9mo ago

Pfizer to Buy Metsera for $4.9 Billion Upfront in Return to Obesity Drugs

7 ARTICLES

9mo ago

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline

Pharmaceuticals

GSK to Buy Nuvalent for $10.6 Billion to Bolster Lung‑Cancer Pipeline

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

Sun Pharma to Buy Organon for $11.75 Billion in All-Cash Deal

Ligand to Buy XOMA Royalty for $739 Million

Biogen to Buy Apellis for $5.6 Billion in Cash, Adding Syfovre and Empaveli

Lilly to Acquire Centessa for $6.3 Billion to Add Orexin Sleep Drugs

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

Merck Ends Revolution Medicines Takeover Talks After Valuation Standoff

Never miss stories about

Pharmaceuticals

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

Pfizer to Buy Metsera for $4.9 Billion Upfront in Return to Obesity Drugs

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline

Never miss stories about

Pharmaceuticals